Long-term effects of intravenous pamidronate in fibrous dysplasia of bone

Bell, 1970, Effects of calcitonin in Paget's disease and polyostotic fibrous dysplasia, J Clin Endocrinol, 31, 283, 10.1210/jcem-31-3-283

Yamamoto, 1983, Suppressive effect of elcatonin, an eel calcitonin analogue, on excessive hydroxyproline excretion in polyostotic fibrous dysplasia (McCune-Albright's syndrome), Endocrinol Japan, 30, 651, 10.1507/endocrj1954.30.651

Morii, 1971, Effects of calcitonin in metastatic bone carcinoma, osteoporosis, polyostotic fibrous dysplasia and hypercalcemia, Endocrinol Japan, 18, 81, 10.1507/endocrj1954.18.81

Hjelmstedt, 1979, A case of Albright's syndrome treated with calcitonin, Acta Orthop Scand, 50, 251, 10.3109/17453677908989764

Cole, 1983, Panostotic fibrous dysplasia: a congenital disorder of bone with unusual facial appearance, bone fragility, hyperphosphataemia and hypophosphatemia, Am J Med Genet, 14, 725, 10.1002/ajmg.1320140414

Long, 1988, Polyostotic fibrous dysplasia with contrasting response to calcitonin and mithramycin: aetiological and therapeutic implications, Ir J Med Sci, 157, 229, 10.1007/BF02949307

Fleisch, 1989, Bisphosphonates: a new class of drugs in diseases of bone and calcium metabolism, Recent Results Cancer Res, 116, 1, 10.1007/978-3-642-83668-8_1

Adamson, 1993, Mineralisation defects with pamidronate therapy for Paget's disease, Lancet, 342, 1459, 10.1016/0140-6736(93)92935-M

Jiang, 1993, Effects of tiludronate on growing bone of baboons: radiologie-pathologie correlations, Calcif Tissue Int, 52, S44